On the latest episode of PSPod, host Alaina Webster is joined by France Mentré, MD, PhD, Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology, Deanna L. Kroetz, PhD, Deputy Editor-in-Chief of Clinical and Translational Science, and Shirley K. Seo, PhD, Associate Editor of Clinical Pharmacology & Therapeutics, to discuss their experiences of how COVID-19 has affected submissions and peer review for the ASCPT Family of Journals. Brian Coughlin, Publisher at Wiley, serves as moderator for the discussion.
Tagged: Pharmacology
ClinPharmPod: Journal Submissions in the Time of COVID
On the latest episode of ClinPharmPod, host Alaina Webster is joined by France Mentré, MD, PhD, Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology, Deanna L. Kroetz, PhD, Deputy Editor-in-Chief of Clinical and Translational Science, and Shirley K. Seo, PhD, Associate Editor of Clinical Pharmacology & Therapeutics, to discuss their experiences of how COVID-19 has affected submissions and peer review for the ASCPT Family of Journals. Brian Coughlin, Publisher at Wiley, serves as moderator for the discussion.
A Holistic and Integrative Approach for Advancing Model‐Informed Drug Development
On this episode of PSPod, Dr. Rajanikanth Madabushi from the US Food and Drug Administration continues our recent discussion on model-informed drug development (MIDD) and its role in the successful implementation of PDUFA VI. This discussion is based on his co-authored Perspective article (with Drs. Yaning Wang and Issam Zineh) “A Holistic and Integrative Approach for Advancing Model‐Informed Drug Development” which published in the January 2019 issue of PSP. The article is available here.
PDUFA VI: It Is Time to Unleash the Full Potential of Model-Informed Drug Development with Drs. Lokesh Jain, Larissa Wenning, and Nitin Mehrotra from Merck
On this episode of PSPod, Drs. Lokesh Jain, Larissa Wenning, and Nitin Mehrotra from Merck discuss the important role model-informed drug development (MIDD) will play in the successful implementation of PDUFA VI. This discussion is based on their Perspective article “PDUFA VI: It’s Time to Unleash the Full Potential of Model-Informed Drug Development” which published in the January 2019 issue of PSP. The article is available here.
Quantitative Systems Toxicology Modeling with guest Dr. Paul Watkins
On today’s episode, Dr. Paul Watkins, the Howard Q. Ferguson Distinguished Professor at Eshelman School of Pharmacy, University of North Carolina at Chapel Hill and the Director of the University of North Carolina Institute for Drug Safety Sciences, discusses quantitative systems toxicology (QST) and quantitative systems pharmacology (QSP) modeling, recent examples of their application, and how they might better inform decision-making in the pharma industry. Dr. Watkins recently wrote a Commentary in PSP related to this topic and it is available here.